Backgrounds: The safety and efficacy of different type of drug-eluting stents (DESs) in patients (pts) with acute myocardial infarction (AMI) are not clarified yet. We compared 6-month angiographic and clinical outcomes of AMI pts who received three major DESs. Methods: A total 355 consecutive AMI pts (Age; 60.62 짹 11.87, Men; 70.7 %) who underwent percutaneous coronary intervention (PCI) with either Sirolimus (SES; Cypher���R, n=116) - or Paclitaxel (PES; Taxus���R, n=153) - or Zotarilimus-eluting stents (ZES; Endeavor���R, n=86) were enrolled for the study. The angiographic and clinical outcomes at 6-month were compared among the three groups. Results: Baseline clinical and procedural characteristics were similar among the three groups. At 6-month, there was a trend toward higher incidence of binary restenosis in the Taxus group. Restenosis percent was higher in PES compared with SES but similar to ZES. Late loss was lower in SES compared with PES and ZES (SES; 0.44 짹0.52 % PES; 0.83 짹0.87% ZES; 0.75 짹 0.63 %, p <0.001). However, clinical outcomes including mortality, myocardial infarction, repeat PCI and major cardiac adverse event (MACE) were not different among three groups (Table). Conclusion: The SES implantation in pts with AMI was associated with lower angiographic restenosis at 6 months compared with PES and ZES. However, these angiographic benefits of SESs were not translated into better clinical outcomes up to 6 months, suggesting longer follow up with larger study population will be needed.